ABSTRACT
Background Clinical genetic laboratories often require comprehensive analysis of chromosomal rearrangements/structural variants (SVs) which can range from gross chromosomal events, such as translocations and inversions, to supernumerary ring/marker chromosomes, and small deletions or duplications. To fully understand the complexity of a specific event and its associated clinical consequences, it is imperative to locate the breakpoint junctions and to resolve the derivative chromosome structure. This task, however, often surpasses the capabilities of conventional short-read sequencing technologies. In contrast, emerging long-read sequencing techniques present a compelling alternative for clinical diagnostics.
Methods Here, the Genomic Medicine Sweden Rare Diseases (GMS-RD) consortium explored the utility of HiFi Revio long-read whole genome sequencing (lrGS) for clinical digital karyotyping of SVs nationwide. The first 16 samples included in this study were collected from all health care regions in Sweden. We established a national pipeline and a shared variant database for variant calling and filtering. The included validation samples cover a spectrum of simple and complex SVs including inversions, translocations and copy number variants.
Results The results from the lrGS analysis match the reported karyotype for 14/16 individuals and 12 known SVs were mapped at nucleotide resolution. A complex rearrangement on chromosome 15 was identified only through read depth analysis and two chromosome 21 rearrangements remained undetected, one of which was mosaic. The average read length ranged from 8.3-18.8 kb and the coverage was >20x for all samples. De novo assembly resulted in a limited number of contigs per individual (N50 range 6-86 Mb) clearly separating the two alleles in most cases, enabling direct characterization of the chromosomal rearrangements.
Conclusions In a national pilot study, we successfully demonstrated the utility of HiFi Revio lrGS as a clinical analysis of chromosomal rearrangements. Based on our results we propose a five-year plan for the wider implementation of lrGS for rare disease diagnostics in Sweden.
Competing Interest Statement
AL has received honoraria from Pacific Biosciences
Funding Statement
Funding was provided by Genomic Medicine Sweden as well as grants to AL from the Swedish Research Council (2017-02936 and 2019-02078), the Stockholm Regional Council and the Swedish Rare Diseases Foundation, and to LF from the Swedish Research Council (2017-01861) and Hjärnfonden (FO2022-0207).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethical Review Board in Sweden approved the study (ethics permit number 2019-04746). Written consent to participate was provided by the subject or their legal guardians. The research conformed to the principles of the Helsinki Declaration.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data from three addtional patients has been included. Changes have been made to the manuscript text and figures
Data Availability
The PacBio HiFi data and individual variant calls will be available through the European '1+ Million Genomes' Initiative that is being set up. As a clinical case data will be stored at the National Genomics Platform managed by Genomic Medicine Sweden, accession number GMS-RD_00002. Data will be made available upon reasonable request through the corresponding authors.
